Page 15 - Dyslipidaemia_newsletter8_2024_Final

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #8 2024

TREATMENT AND ADHERENCE Dyslipidaemia

7. High-intensity statins vs. moderate-intensity statin-ezetimibe combination therapy: A patient centered approach.
Grant JK, Orringer CE. J Clin Lipidol. 2024 Jul 27:S1933-2874(24)00216-2. doi: 10.1016/j.jacl.2024.07.007. Online ahead of
print.
8. Safety and effectiveness of high-intensity statins versus low/moderate-intensity statins plus ezetimibe in patients
with atherosclerotic cardiovascular disease for reaching LDL-C goals: A systematic review and meta-analysis.
Soleimani H, et al. Clin Cardiol. 2024;47(8):e24334.
9. Use of combination therapy is associated with improved LDL-cholesterol management: 1-year follow-up results
from the European observational SANTORINI study. Ray KK, et al. Eur J Prevent Cardiol. 2024 Jun 11:zwae199.

10. Treatment patterns and adherence to lipid-lowering drugs during eight-year follow-up after a coronary heart
disease event. Engebretsen I, et al. Atherosclerosis. 2024 Jun;393:117550.

SPECIAL POPULATIONS

11. Effect of statin use on liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease (NAFLD). Ho
A, et al. J Clin Lipidol. 2024 Jul-Aug;18(4):e501-e508.

12. LDLR variant classification for improved cardiovascular risk prediction in familial hypercholesterolemia. Ibrahim S,
et al. Atherosclerosis. 2024 Oct;397:117610.

13. Lipid-lowering in diabetes: An update. Chait A, et al. Atherosclerosis. 2024 Jul;394:117313.

14. Prediction of cumulative exposure to atherogenic lipids during early adulthood. Wilkins JT, et al. J Am Coll Cardiol.
2024 Sep 10;84(11):961-973. doi: 10.1016/j.jacc.2024.05.070.

15. Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and
prognosis: the SWEDEHEART registry. Schubert J, et al. Eur Heart J. 2024 Sep 1:ehae576. doi: 10.1093/eurheartj/
ehae576. Online ahead of print.

TABLE OF CONTENTS